Nuvectis Pharma
Stock Forecast, Prediction & Price Target
Nuvectis Pharma Financial Estimates
Nuvectis Pharma Revenue Estimates
Nuvectis Pharma EBITDA Estimates
Nuvectis Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $149K 0% | $0 -100% | Avg: $23.06M Low: $23.06M High: $23.06M avg. 0% | Avg: $1.97M Low: $1.97M High: $1.97M avg. -91.45% | Avg: $31.45M Low: $31.45M High: $31.45M avg. 1496.08% | Avg: $75.11M Low: $75.11M High: $75.11M avg. 138.81% |
Net Income
% change YoY
| $-12.88M N/A | $-18.78M -45.79% | $-22.26M -18.48% | Avg: $-29.10M Low: $-27.37M High: $-15.40M avg. -30.73% | Avg: $-33.51M Low: $-30.64M High: $-15.86M avg. -15.17% | Avg: $-6.94M Low: $-6.94M High: $-6.94M avg. 79.26% | Avg: $12.28M Low: $12.28M High: $12.28M avg. 276.86% |
EBITDA
% change YoY
| $-12.89M N/A | $-19.23M -49.17% | $-22.89M -19.04% | Avg: $11.53M Low: $11.53M High: $11.53M avg. 150.36% | Avg: $985.33K Low: $985.33K High: $985.33K avg. -91.45% | Avg: $15.72M Low: $15.72M High: $15.72M avg. 1496.08% | Avg: $37.55M Low: $37.55M High: $37.55M avg. 138.81% |
EPS
% change YoY
| -$1.01 N/A | -$1.48 -46.53% | -$1.43 3.37% | Avg: -$1.41 Low: -$1.76 High: -$0.99 avg. 1.39% | Avg: -$1.56 Low: -$1.97 High: -$1.02 avg. -10.87% | Avg: -$0.45 Low: -$0.45 High: -$0.45 avg. 71.42% | Avg: $0.79 Low: $0.79 High: $0.79 avg. 276.86% |
Operating Expenses
% change YoY
| $12.89M N/A | $19.23M 49.17% | $22.89M 19.04% | Avg: $249.75M Low: $249.75M High: $249.75M avg. 990.78% | Avg: $21.34M Low: $21.34M High: $21.34M avg. -91.45% | Avg: $340.60M Low: $340.60M High: $340.60M avg. 1496.08% | Avg: $813.40M Low: $813.40M High: $813.40M avg. 138.81% |
FAQ
What is Nuvectis Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 77.55% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -27.37M, average is -29.10M and high is -15.40M.
What is Nuvectis Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 385.85% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $23.06M, average is $23.06M and high is $23.06M.
What is Nuvectis Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 84.70% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.76, average is -$1.41 and high is $-0.99.